Kalvista Pharmaceuticals

NMQ:KALV · US4834971032

BiotechnologySmall

360

Value38

Profit price55

Cash yield1

Sales & asset price67

Price/Sales84

EV / Gross Profit23

Price/Book95

Quality56

Returns on capital—

Profit margins39

EBIT Margin14

Gross Profitability64

Cash backing67

Accruals89

Owner Earnings Margin45

Growth68

Sales growth89

Profit growth74

Profit Growth86

Long-Term EPS Growth62

Reinvestment1

Price momentum63

Safety52

Debt load8

Debt serviceability24

Refinancing47

Debt Payback1

Liquidity100

Sentiment45

Analyst ratings3

Expectations trend15

Opinion Changes24

Price Target Upside6

Market mood19

Value Creation7/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Kalvista Pharmaceuticals clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePrivate Company

ExchangeNASDAQGM

Employees256

Websitekalvista.com

ISINUS4834971032

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

Chronic DiseasesGenetic DisorderHematologyAllergyBiotechnologyDiabetesHealth Care

Description

KalVista Pharmaceuticals, Inc. manufactures and sells oral therapies for individuals affected by rare diseases with significant unmet needs worldwide. On July 3, 2025, the company received approval from the U.S. Food and Drug Administration (FDA) fo…

Analysis

Middle-of-the-road

KalVista Pharmaceuticals, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is solid and the balance sheet is adequate. The company scores 7/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

100

—

Price/Book

—

Dividend Yield

—

Value (overall)

100

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Kalvista Pharmaceuticals with its peers

Incyte

NSQ:INCY

CountryUSA

IndustryBiotechnology

SizeLarge

Full Stock Analysis →

Mineralys Therapeutics

NSQ:MLYS

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Dianthus Therapeutics

NAQ:DNTH

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Mink Therapeutics

NAQ:INKT

—

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Vor Biopharma

NSQ:VOR

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Aurinia Pharmaceuticals

NMQ:AUPH

CountryCanada

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →